Nasdaq atai.

Atai Life Sciences (NASDAQ:ATAI) has a recorded annual revenue of $230,000.00. How much profit does Atai Life Sciences generate each year? Atai Life Sciences (NASDAQ:ATAI) has a recorded net income of -$152.38 million.COMPASS Pathways plc (NASDAQ: CMPS) and Atai Life Sciences N.V. (NASDAQ: ATAI) recently debuted on the stock market, fetching billion dollar valuations, while Seelos Therapeutics, Inc. (NASDAQ ...Nov 17, 2023 ... atai Life Sciences N.V. (ATAI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy).4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.

About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. NVIDIA Corporation Common Stock. ATAI Life Sciences N ... 4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the …Nov 10, 2022 · atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ...

Oct 12, 2022 · NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) announced today positive initial results for their Phase 1 clinical trial of KUR-101. KUR ...

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release.ATAI Life Sciences (NASDAQ: ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ...Atai Life Sciences’ (NASDAQ: ATAI) stock fell more than 40% after the primary endpoint of a phase 2a clinical trial examining the use of ketamine treatment to treat depression was not met.NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

ATAI's stock price has decreased by -68.7% in the past year and price targets may not have had time to catch up. Stock Price Forecast According to 4 stock …

With a Buy rating, Baader Helvea initiated coverage on ATAI Life Sciences NV (NASDAQ:ATAI). The price target seems to have been set at $21.00 for ATAI Life Sciences. The stock has a 52-week-high ...

Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 million to advance multiple clinical and discovery programs.ATAI Life Sciences News: This is the News-site for the company ATAI Life Sciences on Markets Insider Indices Commodities Currencies Stocks8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...As of August 2, 2023, the average one-year price target for ATAI Life Sciences N.V. is 12.51. The forecasts range from a low of 5.15 to a high of $22.05. The average price target represents an ...atai Impact, the philanthropic program of atai Life Sciences (NASDAQ: ATAI) and the Multidisciplinary Association for Psychedelic Studies (MAPS) recently announced a $500,000 donation from atai ...

Oct 2, 2023 · NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release. ATAI Life Sciences N.V. Common Shares ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. Based on 2 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $20.00 with a high ...Aug 15, 2022 ... atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming …Atai Life Sciences N.V. (NASDAQ:ATAI)’s largest hedge fund investor is Israel Englander’s Millennium Management which owns 117,716 shares that are worth $205,000. 11.NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...

75.54 -1.56(-2.02%) Gold 2,003.00 +10.20(+0.51%) Atai Life Sciences N.V. (ATAI) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 1.1000 +0.0100 (+0.92%) At close: 01:00PM...1Y 5Y No 1Y chart data available About ATAI ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and …Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021.Sep 21, 2021 · NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ... Aegis Capital initiated coverage on ATAI Life Sciences NV (NASDAQ:ATAI) with a Buy rating. The price target for ATAI Life Sciences is set to $26.00. The stock has a 52-week-high of $22.91 and a 52 ...Clinical-stage biotech DemeRx, which is part of Atai Life Sciences’ (NASDAQ: ATAI) portfolio, has completed phase 1 trials for noribogaine and is now planning to launch a phase 2 trial on a ...Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...

Mar 7, 2023 · According to 6 analyst offering 12-month price targets in the last 3 months, ATAI Life Sciences has an average price target of $15.33 with a high of $23.00 and a low of $9.00. Below is a summary ...

Creso Pharma and Red Light Holland entered into a definitive scheme implementation deed to combine businesses and create The HighBrid Lab

atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ...The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...DemeRx, a subsidiary of Atai Life Sciences (NASDAQ: ATAI), is developing psychedelic ibogaine for the treatment of opioid use disorder and just announced it has begun a phase 1/2a clinical trial on healthy volunteers and recreational drug users. Ibogaine is a dissociative psychoactive compound naturally found in the iboga tree, which is a …Apr 13, 2023 · atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been ... On the other hand, atai (NASDAQ:ATAI)’s Phase 1 clinical trial testing atypical opioid receptor modulator KUR-101 towards Opioid Use Disorder treatment has provided mixed results, which seem to ...ATAI Life Sciences N.V. Common Shares (ATAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, recently ...

Instrument Name Atai Life Sciences N.V. Instrument Symbol (ATAI-Q). Instrument Exchange NASDAQ ; Previous Close 1.1200 ; 52-Week High/Low 3.6500 1.0400 ; Volume ...75.54 -1.56(-2.02%) Gold 2,003.00 +10.20(+0.51%) Atai Life Sciences N.V. (ATAI) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 1.1000 +0.0100 (+0.92%) At close: 01:00PM...Analyst's Opinion · Consensus Rating. Atai Life Sciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...Clinical-stage biotech DemeRx, which is part of Atai Life Sciences’ (NASDAQ: ATAI) portfolio, has completed phase 1 trials for noribogaine and is now planning to launch a phase 2 trial on a ...Instagram:https://instagram. nvidia stock purchasenysearca jdstpgt incamazon stock price targets Aug 15, 2022 ... atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ... best real estate investment coursessurgetrader trustpilot Before this, he was the CFO of atai Life Sciences (Nasdaq: ATAI), where he led a successful IPO, managed the acquisition of multiple mental health therapeutics assets, and raised more than $500 million to advance multiple clinical and discovery programs. dhhorton NEW YORK and BERLIN, Aug. 10, 2023-- atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2023 ...NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ...